China Medical GatewayLoading your healthcare gateway…

Innovative Cancer Medicines in China

Overview

China has become one of the world’s fastest-moving markets for innovative oncology drugs: domestically developed targeted therapies, immunotherapies and antibody-drug conjugates frequently achieve Chinese approval before or alongside international availability, often at substantially lower prices.

This program provides international patients structured access to these novel agents — through hospital pharmacy channels, expanded-access pathways and registered clinical trials at major cancer centers.

Symptoms & Signs

Indications are defined by the underlying cancer and its molecular profile rather than symptoms alone

Disease progressing despite standard first- and second-line therapy

Actionable mutations or biomarkers identified by genomic testing for which novel agents exist

Intolerance of conventional therapy requiring alternative agents

Tumors with rare targets, such as NTRK fusions or RET alterations

No approved standard therapy remaining — the classic clinical-trial situation

Diagnosis

Comprehensive genomic profiling (tissue and liquid biopsy NGS) identifying actionable targets

Pathology review confirming diagnosis and biomarker status

PD-L1, MSI and tumor-mutation-burden testing for immunotherapy suitability

Re-staging imaging establishing the disease baseline

Organ-function assessment confirming eligibility for novel agents

Review of prior therapies documenting standard-care exhaustion

Treatment Options

Domestically developed EGFR, ALK and ROS1 inhibitors for lung cancer, several China-first approvals

Anti-PD-1/PD-L1 immunotherapies across a dozen approved indications

Antibody-drug conjugates for breast, gastric, urothelial and other cancers

CAR-T and other cell therapies for hematologic malignancies

Registered clinical trials offering access to pipeline agents

Named-patient and expanded-access programs where regulations permit

Advanced Technologies & Novel Drug

Central pharmacy channels for domestically approved novel oncology drugs

Next-generation sequencing infrastructure supporting precision prescribing

Phase I and dose-expansion trial units at major cancer centers

Bispecific antibody and ADC platforms in active development

Real-world data programs tracking novel-agent outcomes

Hospital & Specialist

Return to Home